[ad_1]
(Photo from Anatolia)
MANILA – Philippine pharmaceutical company Glovax Biotech has partnered with a Korean vaccine manufacturer to produce EuCorVac-19 in the Philippines, should the government buy 40 million doses of the Covid-19 vaccine.
In a statement, Glovax said it is in discussions with the Department of Commerce and Industry and the Board of Investments for possible investment in the next-generation Covid-19 vaccine production facility.
If the government orders 40 million doses of the vaccine, the company will invest PHP7 billion for the manufacturing plant and the cost of technology transfer, said Glovax, the first and only company to bring the vaccine to the country during the flu pandemic. swine AH1N1 in 2009 to 2010.
“The local Covid-19 vaccine plant is capable of producing 100 million annual doses of the next-generation Covid-19 vaccine and could help ease our burden of waiting for oversupply from other countries,” Glovax added.
The company said that the main executor of the National Task Force against Covid-19 and vaccine czar, Carlito Gálvez Jr., has endorsed Glovax for the Department of Science and Technology.
The pharmaceutical firm will partner with the Korean firm Eubiologics to locally produce EuCorVac-19, which was developed in the United States by POP Biotechnologies.
EuCorVac-19 will initially be produced in South Korea before expanding to other markets such as the Philippines.
“Glovax and Eubiologics are in the process of applying for the emergency use authorization (USA),” Glovax said, adding that the Eubiologics vaccine obtained approval for the combined phase I and phase II clinical trial from the Ministry of Food Safety. and Medicines from South Korea. in January 2021.
In addition to Eubiologics, Glovax has also partnered with another Korean company, LG Chem, to locally produce a pentavalent vaccine that provides immunity against five major diseases: diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type B, an infection responsible for pneumonia and meningitis.
“Glovax’s proposal to produce the next-generation Covid vaccine offers many advantages, as it can capture newer Covid-19 strains and other mutations, as opposed to first-generation Covid-19 vaccines, which are only 22 percent. effective against the new South African strain and other new strains found throughout the world, ”said the local pharmaceutical company.
He added that the storage requirement for EuCorVac-19 is less demanding compared to the first generation of Covid-19 vaccines, as the Eubiologics vaccine can last three months at 25 ° Celsius, or keep it for a longer period between 2 ° C. C and 8 ° C. ° C.
Glovax has sold more than five million doses of vaccines in the Philippines since 2003. The company distributes vaccines against polio, tuberculosis, measles, tetanus and rabies, as well as pentavalent vaccines. (PNA)
[ad_2]
